- Home
- KURA
KURA
Kura Oncology Inc.
as 02-21-2025 4:00pm EST
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as Kura Oncology Inc. KURA prepares to release earnings report on 26 Feb 2025.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 611.7M | IPO Year: | N/A |
| Target Price: | $27.13 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.98 - $24.17 | Next Earning Date: | 02-26-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 280.91% |
Stock Insider Trading Activity of Kura Oncology Inc. (KURA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bair Teresa Brophy | KURA | Chief Legal Officer | Jan 28 '25 | Sell | $7.87 | 7,281 | $57,315.30 | 112,792 | |
| DOYLE THOMAS JAMES | KURA | SVP, Finance & Accounting | Jan 28 '25 | Sell | $7.87 | 4,949 | $38,958.03 | 90,014 | |
| FORD KATHLEEN | KURA | Chief Operating Officer | Jan 28 '25 | Sell | $7.87 | 1,817 | $14,303.24 | 21,367 | |
| Powl Brian T. | KURA | Chief Commercial Officer | Jan 28 '25 | Sell | $7.87 | 1,583 | $12,461.22 | 59,667 | |
| Leoni Mollie | KURA | Chief Medical Officer | Jan 28 '25 | Sell | $7.87 | 4,963 | $39,068.24 | 88,253 | |
| Burrows Francis | KURA | Chief Scientific Officer | Jan 28 '25 | Sell | $7.87 | 2,166 | $17,050.54 | 20,705 |
Latest Kura Oncology Inc. News
KURA Breaking Stock News: Dive into KURA Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
15 days ago
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
16 days ago
Wedbush Adjusts Kura Oncology's Price Target to $26 From $34, Maintains Outperform Rating
GlobeNewswire
17 days ago
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs
MT Newswires
2 months ago
Kura Oncology Promotes Mollie Leoni to Chief Medical Officer
GlobeNewswire
2 months ago
Kura Oncology Announces Senior Executive Promotions
GlobeNewswire
2 months ago
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
Insider Monkey
3 months ago
Why Is Kura Oncology, Inc. (KURA) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
Compare KURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KURA Kura Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.